BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31915807)

  • 21. Treatment stratification of respiratory syncytial virus infection in allogeneic stem cell transplantation.
    Balassa K; Salisbury R; Watson E; Lubowiecki M; Tseu B; Maouche N; Jeffery K; Misbah SA; Benamore R; Rowley L; Barton D; Pawson R; Danby R; Rocha V; Peniket A
    J Infect; 2019 Jun; 78(6):461-467. PubMed ID: 30965067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections.
    Shah DP; Ghantoji SS; Shah JN; El Taoum KK; Jiang Y; Popat U; Hosing C; Rondon G; Tarrand JJ; Champlin RE; Chemaly RF
    J Antimicrob Chemother; 2013 Aug; 68(8):1872-80. PubMed ID: 23572228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter investigation of respiratory syncytial viral infection in children with hematopoietic cell transplantation.
    Rowan CM; Gertz SJ; Zinter MS; Moffet J; Bajwa RPS; Barnum JL; Kong M;
    Transpl Infect Dis; 2018 Jun; 20(3):e12882. PubMed ID: 29573141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis.
    Tejada S; Martinez-Reviejo R; Karakoc HN; Peña-López Y; Manuel O; Rello J
    Adv Ther; 2022 Sep; 39(9):4037-4051. PubMed ID: 35876973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
    DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
    N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative.
    Beaird OE; Freifeld A; Ison MG; Lawrence SJ; Theodoropoulos N; Clark NM; Razonable RR; Alangaden G; Miller R; Smith J; Young JA; Hawkinson D; Pursell K; Kaul DR
    Transpl Infect Dis; 2016 Apr; 18(2):210-5. PubMed ID: 26923867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
    Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.
    Manothummetha K; Mongkolkaew T; Tovichayathamrong P; Boonyawairote R; Meejun T; Srisurapanont K; Phongkhun K; Sanguankeo A; Torvorapanit P; Moonla C; Plongla R; Kates OS; Avery RK; Nematollahi S; Permpalung N
    Clin Microbiol Infect; 2023 Oct; 29(10):1272-1279. PubMed ID: 37116860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
    Zamora MR; Budev M; Rolfe M; Gottlieb J; Humar A; Devincenzo J; Vaishnaw A; Cehelsky J; Albert G; Nochur S; Gollob JA; Glanville AR
    Am J Respir Crit Care Med; 2011 Feb; 183(4):531-8. PubMed ID: 20851929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
    Ahmad A; Eze K; Noulin N; Horvathova V; Murray B; Baillet M; Grey L; Mori J; Adda N
    N Engl J Med; 2022 Feb; 386(7):655-666. PubMed ID: 35172056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.
    Seo S; Campbell AP; Xie H; Chien JW; Leisenring WM; Englund JA; Boeckh M
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):589-96. PubMed ID: 23298855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
    Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome.
    Avetisyan G; Mattsson J; Sparrelid E; Ljungman P
    Transplantation; 2009 Nov; 88(10):1222-6. PubMed ID: 19935377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections.
    Shah DP; Ghantoji SS; Ariza-Heredia EJ; Shah JN; El Taoum KK; Shah PK; Nesher L; Hosing C; Rondon G; Champlin RE; Chemaly RF
    Blood; 2014 May; 123(21):3263-8. PubMed ID: 24700783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
    Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
    J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral GS-5806 activity in a respiratory syncytial virus challenge study.
    DeVincenzo JP; Whitley RJ; Mackman RL; Scaglioni-Weinlich C; Harrison L; Farrell E; McBride S; Lambkin-Williams R; Jordan R; Xin Y; Ramanathan S; O'Riordan T; Lewis SA; Li X; Toback SL; Lin SL; Chien JW
    N Engl J Med; 2014 Aug; 371(8):711-22. PubMed ID: 25140957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
    Sadoff J; De Paepe E; DeVincenzo J; Gymnopoulou E; Menten J; Murray B; Rosemary Bastian A; Vandebosch A; Haazen W; Noulin N; Comeaux C; Heijnen E; Eze K; Gilbert A; Lambkin-Williams R; Schuitemaker H; Callendret B
    J Infect Dis; 2022 Aug; 226(3):396-406. PubMed ID: 33400792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
    Falsey AR; Williams K; Gymnopoulou E; Bart S; Ervin J; Bastian AR; Menten J; De Paepe E; Vandenberghe S; Chan EKH; Sadoff J; Douoguih M; Callendret B; Comeaux CA; Heijnen E;
    N Engl J Med; 2023 Feb; 388(7):609-620. PubMed ID: 36791161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.